查詢結果分析
相關文獻
- Denosumab for Breast Cancer with Bone Metastases-induced Hypercalcemia Complicated with Acute Renal Failure
- The Effects of Pesticides Chlordane, Dieldrin and Endosulfan on the Growth of Human Breast Cancer Cell Lines MCF-7 and SK-BR-3
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- Cystic Hypersecretory Intraductal Carcinoma of the Breast--Case Report
- Timing of Shoulder Exercise after Modified Radical Mastectomy: A Prospective Study
- 前哨淋巴掃描診斷乳癌早期轉移
- Measurement of the Quality of Life during Different Clinical Phases of Breast Cancer
- The Prognostic Significance of Pathologic Characteristics of Breast Cancer Patients in Taiwan
- 趨勢面分析法在癌症地圖繪製上的應用: 以臺灣的乳癌死亡率為例
- 使用Tamoxifen治療乳癌
頁籤選單縮合
題名 | Denosumab for Breast Cancer with Bone Metastases-induced Hypercalcemia Complicated with Acute Renal Failure=以Denosumab治療骨轉移乳癌患者合併腎衰竭之高血鈣 |
---|---|
作者 | 郭政裕; 趙大中; Kuo, Chen-yu; Chao, Ta-chung; |
期刊 | 臺灣癌症醫學雜誌 |
出版日期 | 20150600 |
卷期 | 2:2 2015.06[民104.06] |
頁次 | 頁172-176 |
分類號 | 418.2183 |
語文 | eng |
關鍵詞 | 乳癌; 高血鈣; Breast cancer; Denosumab; Hypercalcemia; |
中文摘要 | 癌症相關高血鈣在乳癌合併骨轉移患者是個比較常見的併發症,嚴重者可能導致腎 衰竭及意識昏迷。治療的黃金準則為充足水份補充、靜脈注射雙磷酸鹽藥物以及在確定 低血容已矯正恢復後可以給予亨利氏環利尿劑。雙磷酸鹽藥物因有使腎功能變差之可能 性,是否可用來治療癌症相關高血鈣併發嚴重腎功能損傷之患者,仍有爭議。細胞核因 子 Kappa B 受體活化因子之配體(RANK-L)是促使蝕骨細胞分化、具有活性以及存活的一 個必需訊息傳遞訊號。Denosumab 為一全人類成份的抗體,可以中和掉 RANK-L 而使骨 頭表面的蝕骨細胞喪失,進而抑制骨頭的再吸收。我們在此報告一個以 denosumab 治療 乳癌相關高血鈣併發腎衰竭成功的患者。 |
英文摘要 | Cancer-related hypercalcemia is a relative common complication from breast cancer with bone metastasis and may cause renal failure and coma in severe condition. The cornerstone of treatment is vigorous hydration, intravenous bisphosphonates, and loop diuretic agent only after corrected hypovolemia. Bisphosphonates is related deterioration of renal function and is controversial when administered in cancer-related hypercalcemia complicated markedly renal deterioration. The receptor activator of nuclear factor-kappa Bligand (RANK-L) is an essential signal to stimulate differentiation, activity and survival of osteoclast. Denosumab, a fully human antibody which neutrolizes RANK-L leading to the loss of osteoclasts from bone surface and inhibition of bone resorption. Here, we present a case report of breast cancer-related hypercalcemia complicated renal failure was successfully treated by denosumab. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。